211 related articles for article (PubMed ID: 32955182)
21. Pomalidomide for multiple myeloma.
Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
[TBL] [Abstract][Full Text] [Related]
22. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
Bjorklund CC; Kang J; Amatangelo M; Polonskaia A; Katz M; Chiu H; Couto S; Wang M; Ren Y; Ortiz M; Towfic F; Flynt JE; Pierceall W; Thakurta A
Leukemia; 2020 Apr; 34(4):1197-1201. PubMed ID: 31719682
[No Abstract] [Full Text] [Related]
23. Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships.
Burslem GM; Ottis P; Jaime-Figueroa S; Morgan A; Cromm PM; Toure M; Crews CM
ChemMedChem; 2018 Aug; 13(15):1508-1512. PubMed ID: 29870139
[TBL] [Abstract][Full Text] [Related]
24. What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma.
Costa BA; Mouhieddine TH; Richter J
Target Oncol; 2022 Jul; 17(4):383-405. PubMed ID: 35771402
[TBL] [Abstract][Full Text] [Related]
25. Novel immunomodulatory compounds in multiple myeloma.
Saini N; Mahindra A
Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
[TBL] [Abstract][Full Text] [Related]
26. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
[TBL] [Abstract][Full Text] [Related]
27. Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug-induced thrombocytopenia.
Tochigi T; Miyamoto T; Hatakeyama K; Sakoda T; Ishihara D; Irifune H; Shima T; Kato K; Maeda T; Ito T; Handa H; Akashi K; Kikushige Y
Blood; 2020 Jun; 135(24):2146-2158. PubMed ID: 32219443
[TBL] [Abstract][Full Text] [Related]
28. Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms.
Guo H; Yang J; Wang H; Liu X; Liu Y; Zhou K
Front Immunol; 2022; 13():1017990. PubMed ID: 36311747
[TBL] [Abstract][Full Text] [Related]
29. RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation.
Zhou N; Gutierrez-Uzquiza A; Zheng XY; Chang R; Vogl DT; Garfall AL; Bernabei L; Saraf A; Florens L; Washburn MP; Illendula A; Bushweller JH; Busino L
Leukemia; 2019 Aug; 33(8):2006-2021. PubMed ID: 30760870
[TBL] [Abstract][Full Text] [Related]
30. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
Patil A; Manzano M; Gottwein E
Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
[TBL] [Abstract][Full Text] [Related]
31. The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience.
Charlinski G; Grzasko N; Jurczyszyn A; Janczarski M; Szeremet A; Waszczuk-Gajda A; Bernatowicz P; Swiderska A; Guzicka-Kazimierczak R; Lech-Maranda E; Szczepaniak A; Wichary R; Dmoszynska A
Eur J Haematol; 2018 Sep; 101(3):354-361. PubMed ID: 29882602
[TBL] [Abstract][Full Text] [Related]
32. A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders.
Kopp KO; Greer ME; Glotfelty EJ; Hsueh SC; Tweedie D; Kim DS; Reale M; Vargesson N; Greig NH
Biomolecules; 2023 Apr; 13(5):. PubMed ID: 37238617
[TBL] [Abstract][Full Text] [Related]
33. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs.
Gemechu Y; Millrine D; Hashimoto S; Prakash J; Sanchenkova K; Metwally H; Gyanu P; Kang S; Kishimoto T
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):11802-11807. PubMed ID: 30373817
[TBL] [Abstract][Full Text] [Related]
34. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Lacy MQ; Tefferi A
Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
[TBL] [Abstract][Full Text] [Related]
35. Immunomodulatory Drugs for the Treatment of B Cell Malignancies.
Ioannou N; Jain K; Ramsay AG
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445275
[TBL] [Abstract][Full Text] [Related]
36. Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma.
Gooding S; Ansari-Pour N; Kazeroun M; Karagoz K; Polonskaia A; Salazar M; Fitzsimons E; Sirinukunwattana K; Chavda S; Ortiz Estevez M; Towfic F; Flynt E; Pierceall W; Royston D; Yong K; Ramasamy K; Vyas P; Thakurta A
Blood; 2022 Oct; 140(16):1816-1821. PubMed ID: 35853156
[TBL] [Abstract][Full Text] [Related]
37. Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways.
Hideshima T; Ogiya D; Liu J; Harada T; Kurata K; Bae J; Massefski W; Anderson KC
Leukemia; 2021 Jan; 35(1):177-188. PubMed ID: 32238854
[TBL] [Abstract][Full Text] [Related]
38. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
Dimopoulos K; Søgaard Helbo A; Fibiger Munch-Petersen H; Sjö L; Christensen J; Sommer Kristensen L; Asmar F; Hermansen NEU; O'Connel C; Gimsing P; Liang G; Grønbaek K
Mol Oncol; 2018 Feb; 12(2):180-195. PubMed ID: 29130642
[TBL] [Abstract][Full Text] [Related]
39. The molecular mechanism of thalidomide analogs in hematologic malignancies.
Lindner S; Krönke J
J Mol Med (Berl); 2016 Dec; 94(12):1327-1334. PubMed ID: 27492707
[TBL] [Abstract][Full Text] [Related]
40. Homo-PROTACs for the Chemical Knockdown of Cereblon.
Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J
ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]